Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients
Multiple doses of alemtuzumab for immunosuppressive therapy of patients with hematologic malignancies and hematopoietic stem cell transplant have been associated with a high rate of infection. In transplantation, limited alemtuzumab dosing has been successfully used as induction immunosuppression. T...
Saved in:
| Main Authors: | Adam Kaplan, Jo-Anne H. Young, Raja Kandaswamy, Danielle Berglund, Bettina M. Knoll, Gretchen Sieger, Winston Cavert, Arthur Matas, Karam M. Obeid |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2020/8883183 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Thrombotic Microangiopathy After Kidney Pancreas Transplant Managed With Eculizumab and a Calcineurin Inhibitor-free Basiliximab/Belatacept Maintenance Regimen: Between a Rock and a Hard Place
by: Jeanne M. Chen, BS, PharmD, BCPS, et al.
Published: (2025-07-01) -
Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study
by: Tim D. A. Swaab, et al.
Published: (2025-07-01) -
Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
by: BL Johnston, et al.
Published: (2006-01-01) -
Gut microbiome dysregulation in noninfectious uveitis
by: Mingzhu Liu, et al.
Published: (2025-07-01)